| scholarly article | Q13442814 |
| P50 | author | Christophe Baudouin | Q37616711 |
| Andrea Leonardi | Q87781040 | ||
| P2093 | author name string | Marc Labetoulle | |
| Francisco C Figueiredo | |||
| Dahlia Ismail | |||
| Mourad Amrane | |||
| Elisabeth M Messmer | |||
| Maite Sainz-de-la-Maza | |||
| Jean-Sébastien Garrigue | |||
| P2860 | cites work | Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. | Q31775977 |
| Diagnosing the severity of dry eye: a clear and practical algorithm | Q34092386 | ||
| Cyclosporine A delivery to the eye: A pharmaceutical challenge | Q35577456 | ||
| Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb | Q35854966 | ||
| Etiology, prevalence, and treatment of dry eye disease | Q37288773 | ||
| Treatment of dry eye disease by the non-ophthalmologist | Q37317581 | ||
| The association between symptoms of discomfort and signs in dry eye. | Q37641435 | ||
| Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery | Q38133883 | ||
| Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting | Q38151227 | ||
| Clinical guidelines for management of dry eye associated with Sjögren disease. | Q38424517 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting | Q38733230 | ||
| Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease | Q38816983 | ||
| Patients' perception of DED and its relation with time to diagnosis and quality of life: an international and multilingual survey | Q39162328 | ||
| Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts | Q39185845 | ||
| Evidence of seasonality and effects of psychrometry in dry eye disease | Q39829599 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Pan-European survey of the topical ocular use of cyclosporine A. | Q42653046 | ||
| A new approach for better comprehension of diseases of the ocular surface | Q44020701 | ||
| The lack of association between signs and symptoms in patients with dry eye disease | Q45122466 | ||
| Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits | Q46259324 | ||
| American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
| Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - a randomised comparative study. | Q50451132 | ||
| Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. | Q53620228 | ||
| One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. | Q53836361 | ||
| A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. | Q54222666 | ||
| Ophthalmologist Perceptions Regarding Treatment of Moderate-to-Severe Dry Eye: Results of a Physician Survey | Q61759590 | ||
| P433 | issue | 1 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 125-131 | |
| P577 | publication date | 2018-03-15 | |
| P1433 | published in | British Journal of Ophthalmology | Q13443571 |
| P1476 | title | Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies | |
| P478 | volume | 103 |
Search more.